Clinical Trial Update: Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of Merck's Broad Spectrum HPV Vaccine (V502-002) completed. Results were posted in 2011 and evaluated safety and immunogenicity ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Human Papillomavirus Infection
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Broad Spectrum HPV Vaccine

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Papilloma Virus, Cervical Cancer | Phase 1 | Status: COMPLETED | Results posted: 2011-06-21